IMRX vs. DOCS

Last updated Jun 4, 2026

IMRX (Immuneering Corporation) and DOCS (Doximity, Inc.) are both stocks. Both are in the Healthcare sector — IMRX in Biotechnology, DOCS in Health Information Services. Over the past 3 years, IMRX returned -19.59%/yr vs -13.96%/yr for DOCS. At a 0.17 correlation, their price movements are largely independent.

Performance

IMRX vs. DOCS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Immuneering Corporation (IMRX) and Doximity, Inc. (DOCS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, IMRX achieves a -30.85% return, which is significantly higher than DOCS's -52.48% return.

IMRX

• 1D: 6.31%
• 1M: -15.51%
• YTD: -30.85%
• 6M: -32.49%
• 1Y: 132.14%
• 3Y*: -19.59%
• 5Y*: —
• 10Y*: —

DOCS

• 1D: -2.19%
• 1M: -15.47%
• YTD: -52.48%
• 6M: -59.17%
• 1Y: -60.68%
• 3Y*: -13.96%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IMRX vs. DOCS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
IMRX Immuneering Corporation	-30.85%	199.09%	-70.07%	51.55%	-70.01%	-8.07%
DOCS Doximity, Inc.	-52.48%	-17.06%	90.41%	-16.45%	-33.05%	-19.01%

Correlation

The correlation between IMRX and DOCS is 0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.03
Correlation (3Y) Calculated over the trailing 3-year period	0.15
Correlation (All Time) Calculated using the full available price history since Aug 2, 2021	0.17

The correlation between IMRX and DOCS shifts across timeframes, from 0.03 (1 year) to 0.17 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap IMRX : $294.20M DOCS : $4.10B
EPS IMRX : -$293.00 DOCS : $0.98
PB Ratio IMRX : 0.00 DOCS : 4.32
Total Revenue (TTM) IMRX : $0.00 DOCS : $644.86M
Gross Profit (TTM) IMRX : -$698.89K DOCS : $574.54M
EBITDA (TTM) IMRX : -$15.38B DOCS : $245.76M

Return for Risk

IMRX vs. DOCS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IMRX

IMRX Risk / Return Rank: 76
IMRX Sharpe Ratio Rank: 73
IMRX Sortino Ratio Rank: 77
IMRX Omega Ratio Rank: 81
IMRX Calmar Ratio Rank: 78
IMRX Martin Ratio Rank: 71

DOCS

DOCS Risk / Return Rank: 6
DOCS Sharpe Ratio Rank: 3
DOCS Sortino Ratio Rank: 4
DOCS Omega Ratio Rank: 3
DOCS Calmar Ratio Rank: 10
DOCS Martin Ratio Rank: 8

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IMRX vs. DOCS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Immuneering Corporation (IMRX) and Doximity, Inc. (DOCS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IMRX	DOCS	Difference
Sharpe ratio Return per unit of total volatility	1.07	-1.12	+2.19
Sortino ratio Return per unit of downside risk	2.16	-1.71	+3.88
Omega ratio Gain probability vs. loss probability	1.31	0.75	+0.56
Calmar ratio Return relative to maximum drawdown	2.40	-0.80	+3.20
Martin ratio Return relative to average drawdown	3.98	-1.38	+5.37
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

IMRX vs. DOCS - Sharpe Ratio Comparison

The current IMRX Sharpe Ratio is 1.07, which is higher than the DOCS Sharpe Ratio of -1.12. The chart below compares the historical Sharpe Ratios of IMRX and DOCS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	IMRX	DOCS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.07	-1.12	+2.19
Sharpe Ratio (All Time) Calculated using the full available price history	-0.21	-0.25	+0.03

Drawdowns

IMRX vs. DOCS - Drawdown Comparison

The maximum IMRX drawdown since its inception was -96.86%, which is greater than DOCS's maximum drawdown of -82.35%. Use the drawdown chart below to compare losses from any high point for IMRX and DOCS.

Drawdown Indicators

	IMRX	DOCS	Difference
Max Drawdown Largest peak-to-trough decline	-96.86%	-82.35%	-14.51%
Max Drawdown (1Y) Largest decline over 1 year	-55.35%	-76.03%	+20.68%
Max Drawdown (3Y) Largest decline over 3 years	-90.98%	-78.34%	-12.64%
Current Drawdown Current decline from peak	-86.14%	-79.38%	-6.76%
Average Drawdown Average peak-to-trough decline	-77.60%	-57.10%	-20.50%
Ulcer Index Depth and duration of drawdowns from previous peaks	33.32%	43.84%	-10.52%

Volatility

IMRX vs. DOCS - Volatility Comparison

Immuneering Corporation (IMRX) and Doximity, Inc. (DOCS) have volatilities of 32.23% and 32.24%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IMRX	DOCS	Difference
Volatility (1M) Calculated over the trailing 1-month period	32.23%	32.24%	-0.01%
Volatility (6M) Calculated over the trailing 6-month period	78.61%	46.16%	+32.45%
Volatility (1Y) Calculated over the trailing 1-year period	123.87%	54.70%	+69.17%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	114.62%	69.08%	+45.54%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	114.62%	69.08%	+45.54%

Dividends

IMRX vs. DOCS - Dividend Comparison

Neither IMRX nor DOCS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both IMRX and DOCS in my portfolio?

IMRX and DOCS have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, IMRX or DOCS?

DOCS has higher volatility (32.24%) compared to IMRX (32.23%). In terms of maximum drawdown, IMRX dropped -96.86% vs DOCS's -82.35%.

Which has better risk-adjusted returns?

IMRX currently has the higher Sharpe Ratio (1.07 vs -1.12), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.